Avan Jaff, MD
Internal Medicine · Cleveland, TNNPI 1316406614
Payments from drug & device makers
Across 116 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$381
- Pfizer$295
- Abbott$155
- Lundbeck LLC$93
- Amgen$91
- AstraZeneca$80
- plus $917 from 26 others
What the payments were for
- Food & beverage$2,013100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $381 |
| Pfizer | 18 | $295 |
| Abbott | 7 | $155 |
| Lundbeck LLC | 4 | $93 |
| Amgen | 6 | $91 |
| AstraZeneca | 5 | $80 |
| Dexcom, Inc. | 4 | $76 |
| Medtronic | 4 | $75 |
| Shield Therapeutics Inc | 4 | $67 |
| Astellas Pharma US Inc | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Bayer | 2 | $40 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Merck | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Nevro Corp. | 1 | $20 |
| Globus Medical | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| GSK | 1 | $15 |
| AbbVie | 1 | $13 |
How this compares
$2,013 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 77 | $101,681 |
| OzempicSemaglutide | 50 | $82,201 |
| MounjaroTirzepatide | 50 | $71,803 |
| EliquisApixaban | 41 | $42,648 |
| XareltoRivaroxaban | 34 | $39,760 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $27,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,305 |
| MyrbetriqMirabegron | 21 | $23,543 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $23,308 |
| LinzessLinaclotide | 19 | $20,717 |
| UbrelvyUbrogepant | 18 | $18,704 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $14,453 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,643 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,670 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $7,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $381 | $82,20150 claims |
| Lilly USA, LLCMounjaro | $32 | $71,80350 claims |
| PfizerEliquis | $295 | $42,64841 claims |
| AbbVieLinzess, Ubrelvy | $13 | $39,42037 claims |
| AstraZenecaBreztri Aerosphere | $80 | $27,07537 claims |
| GSKTrelegy Ellipta | $15 | $24,30530 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $23,54321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Cleveland
- Charles RudolphCleveland$22K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.